Actavis confirmed that the United States District Court for the Southern District of Florida has found United States Patent No. 6,773,720 valid and infringed by Actavis' generic version of Shire's Lialda. Actavis is reviewing the court's decision and will evaluate all available options, including an appeal. Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis and for the maintenance of remission of UC. Actavis' Abbreviated New Drug Application for its generic version of Lialda is currently pending with the FDA.